
## Marco Presta

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4501649/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine and Growth Factor Reviews, 2005, 16, 159-178.	7.2	1,126
2	Internalization of HIV-1 Tat Requires Cell Surface Heparan Sulfate Proteoglycans. Journal of Biological Chemistry, 2001, 276, 3254-3261.	3.4	635
3	Bone Marrow Neovascularization, Plasma Cell Angiogenic Potential, and Matrix Metalloproteinase-2 Secretion Parallel Progression of Human Multiple Myeloma. Blood, 1999, 93, 3064-3073.	1.4	537
4	Human Erythropoietin Induces a Pro-Angiogenic Phenotype in Cultured Endothelial Cells and Stimulates Neovascularization In Vivo. Blood, 1999, 93, 2627-2636.	1.4	461
5	Purification of a factor from human placenta that stimulates capillary endothelial cell protease production, DNA synthesis, and migration Proceedings of the National Academy of Sciences of the United States of America, 1986, 83, 2091-2095.	7.1	335
6	Complexity and Complementarity of Outer Membrane Protein A Recognition by Cellular and Humoral Innate Immunity Receptors. Immunity, 2005, 22, 551-560.	14.3	271
7	Purification from a human hepatoma cell line of a basic fibroblast growth factor-like molecule that stimulates capillary endothelial cell plasminogen activator production, DNA synthesis, and migration Molecular and Cellular Biology, 1986, 6, 4060-4066.	2.3	270
8	Mammalian Tumor Xenografts Induce Neovascularization in Zebrafish Embryos. Cancer Research, 2007, 67, 2927-2931.	0.9	245
9	Both normal and tumor cells produce basic fibroblast growth factor. Journal of Cellular Physiology, 1986, 129, 273-276.	4.1	234
10	The gelatin sponge–chorioallantoic membrane assay. Nature Protocols, 2006, 1, 85-91.	12.0	229
11	The zebrafish/tumor xenograft angiogenesis assay. Nature Protocols, 2007, 2, 2918-2923.	12.0	218
12	Nerve growth factor–endothelial cell interaction leads to angiogenesis in vitro and in vivo. FASEB Journal, 2002, 16, 1307-1309.	0.5	214
13	Cutting Edge: Extracellular High Mobility Group Box-1 Protein Is a Proangiogenic Cytokine. Journal of Immunology, 2006, 176, 12-15.	0.8	212
14	New Model for the Study of Angiogenesis and Antiangiogenesis in the Chick Embryo Chorioallantoic Membrane: The Gelatin Sponge/ Chorioallantoic Membrane Assay. Journal of Vascular Research, 1997, 34, 455-463.	1.4	199
15	Basic fibroblast growth factor modulates integrin expression in microvascular endothelial cells Molecular Biology of the Cell, 1993, 4, 973-982.	2.1	195
16	Evidence for characteristic vascular patterns in solid tumours: quantitative studies using corrosion casts. British Journal of Cancer, 1999, 80, 724-732.	6.4	186
17	Nitric Oxide Promotes Proliferation and Plasminogen Activator Production by Coronary Venular Endothelium Through Endogenous bFGF. Circulation Research, 1997, 80, 845-852.	4.5	182
18	Selective recognition of fibroblast growth factor-2 by the long pentraxin PTX3 inhibits angiogenesis. Blood, 2004, 104, 92-99.	1.4	181

#	Article	IF	CITATIONS
19	Interaction of HIV-1 Tat Protein with Heparin. Journal of Biological Chemistry, 1997, 272, 11313-11320.	3.4	179
20	Distinct Role of Fibroblast Growth Factor-2 and Vascular Endothelial Growth Factor on Tumor Growth and Angiogenesis. American Journal of Pathology, 2003, 162, 1913-1926.	3.8	167
21	Role of the soluble pattern recognition receptor PTX3 in vascular biology. Journal of Cellular and Molecular Medicine, 2007, 11, 723-738.	3.6	166
22	Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood, 1999, 93, 3064-73.	1.4	166
23	Gremlin is a novel agonist of the major proangiogenic receptor VEGFR2. Blood, 2010, 116, 3677-3680.	1.4	163
24	Endogenous Basic Fibroblast Growth Factor Is Implicated in the Vascularization of the Chick Embryo Chorioallantoic Membrane. Developmental Biology, 1995, 170, 39-49.	2.0	158
25	Fibroblast growth factors (FGFs) in cancer: FGF traps as a new therapeutic approach. , 2017, 179, 171-187.		152
26	Human erythropoietin induces a pro-angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Blood, 1999, 93, 2627-36.	1.4	145
27	α <sub>v</sub> β <sub>3</sub> Integrin Mediates the Cell-adhesive Capacity and Biological Activity of Basic Fibroblast Growth Factor (FGF-2) in Cultured Endothelial Cells. Molecular Biology of the Cell, 1997, 8, 2449-2461.	2.1	140
28	Basic fibroblast growth factor is released from endothelial extracellular matrix in a biologically active form. Journal of Cellular Physiology, 1989, 140, 68-74.	4.1	137
29	Erythropoietin as an angiogenic factor. European Journal of Clinical Investigation, 2003, 33, 891-896.	3.4	135
30	Inhibition of angiogenesis and tumor growth by SCH221153, a dual alpha(v)beta3 and alpha(v)beta5 integrin receptor antagonist. Cancer Research, 2001, 61, 2232-8.	0.9	135
31	Fibroblast Growth Factors/Fibroblast Growth Factor Receptors as Targets for the Development of Anti-Angiogenesis Strategies. Current Pharmaceutical Design, 2007, 13, 2025-2044.	1.9	134
32	The mitogenic signaling pathway but not the plasminogen activator-inducing pathway of basic fibroblast growth factor is mediated through protein kinase C in fetal bovine aortic endothelial cells Journal of Cell Biology, 1989, 109, 1877-1884.	5.2	126
33	Generation of Biologically Active Angiostatin Kringle 1–3 by Activated Human Neutrophils. Journal of Immunology, 2002, 168, 5798-5804.	0.8	125
34	HIV-tat protein is a heparin-binding angiogenic growth factor. Oncogene, 1996, 12, 289-97.	5.9	125
35	Cutting Edge: Proangiogenic Properties of Alternatively Activated Dendritic Cells. Journal of Immunology, 2005, 175, 2788-2792.	0.8	124
36	Osteopontin (Eta-1) and Fibroblast Growth Factor-2 Cross-Talk in Angiogenesis. Journal of Immunology, 2003, 171, 1085-1093.	0.8	123

#	Article	IF	CITATIONS
37	Interaction of angiogenic basic fibroblast growth factor with endothelial cell heparan sulfate proteoglycans. International Journal of Clinical and Laboratory Research, 1996, 26, 15-23.	1.0	121
38	Bone Marrow Neovascularization, Plasma Cell Angiogenic Potential, and Matrix Metalloproteinase-2 Secretion Parallel Progression of Human Multiple Myeloma. Blood, 1999, 93, 3064-3073.	1.4	119
39	Bone morphogenic protein antagonist Drm/gremlin is a novel proangiogenic factor. Blood, 2007, 109, 1834-1840.	1.4	118
40	Fibroblast Growth Factor Receptor-1 Is Essential for In Vitro Cardiomyocyte Development. Circulation Research, 2003, 93, 414-420.	4.5	117
41	Dendritic cell–endothelial cell cross-talk in angiogenesis. Trends in Immunology, 2007, 28, 385-392.	6.8	115
42	Inflammatory cells andÂchemokines sustain FGF2-induced angiogenesis. European Cytokine Network, 2009, 20, 39-50.	2.0	114
43	A form of human basic fibroblast growth factor with an extended amino terminus. Biochemical and Biophysical Research Communications, 1987, 144, 543-550.	2.1	112
44	Long-Pentraxin 3 Derivative as a Small-Molecule FGF Trap for Cancer Therapy. Cancer Cell, 2015, 28, 225-239.	16.8	111
45	Multiple Interactions of HIV-I Tat Protein with Size-defined Heparin Oligosaccharides. Journal of Biological Chemistry, 1999, 274, 28198-28205.	3.4	110
46	Basic Fibroblast Growth Factor–Induced Angiogenic Phenotype in Mouse Endothelium. Arteriosclerosis, Thrombosis, and Vascular Biology, 1997, 17, 454-464.	2.4	108
47	The Basic Domain in HIV-1 Tat Protein as a Target for Polysulfonated Heparin-mimicking Extracellular Tat Antagonists. Journal of Biological Chemistry, 1998, 273, 16027-16037.	3.4	105
48	Antiangiogenic and Vascular-Targeting Activity of the Microtubule-Destabilizingtrans-Resveratrol Derivative 3,5,4′-Trimethoxystilbene. Molecular Pharmacology, 2005, 67, 1451-1459.	2.3	104
49	Heparin Derivatives as Angiogenesis Inhibitors. Current Pharmaceutical Design, 2003, 9, 553-566.	1.9	102
50	Cell membrane GM1 ganglioside is a functional coreceptor for fibroblast growth factor 2. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 4367-4372.	7.1	101
51	Identification of an Antiangiogenic FGF2-binding Site in the N Terminus of the Soluble Pattern Recognition Receptor PTX3. Journal of Biological Chemistry, 2006, 281, 22605-22613.	3.4	101
52	Shedding of Membrane Vesicles Mediates Fibroblast Growth Factor-2 Release from Cells. Journal of Biological Chemistry, 2003, 278, 51911-51919.	3.4	99
53	Cutting Edge: IL-1β Mediates the Proangiogenic Activity of Osteopontin-Activated Human Monocytes. Journal of Immunology, 2006, 177, 4267-4270.	0.8	97
54	Modulation of Fibroblast Growth Factor-2 Receptor Binding, Signaling, and Mitogenic Activity by Heparin-Mimicking Polysulfonated Compounds. Molecular Pharmacology, 1999, 56, 204-213.	2.3	95

#	Article	IF	CITATIONS
55	HIV-1 Tat protein and endothelium: from protein/cell interaction to AIDS-associated pathologies. Angiogenesis, 2002, 5, 141-151.	7.2	93
56	Thrombospondin 1 as a scavenger for matrix-associated fibroblast growth factor 2. Blood, 2003, 102, 4399-4406.	1.4	93
57	Pentraxin 3 Inhibits Fibroblast Growth Factor 2–Dependent Activation of Smooth Muscle Cells In Vitro and Neointima Formation In Vivo. Arteriosclerosis, Thrombosis, and Vascular Biology, 2005, 25, 1837-1842.	2.4	93
58	The discovery of angiogenic factors:. General Pharmacology, 2000, 35, 227-231.	0.7	92
59	Human vitreous in proliferative diabetic retinopathy: Characterization and translational implications. Progress in Retinal and Eye Research, 2019, 72, 100756.	15.5	91
60	Sex hormones modulate the synthesis of basic fibroblast growth factor in human endometrial adenocarcinoma cells: Implications for the neovascularization of normal and neoplastic endometrium. Journal of Cellular Physiology, 1988, 137, 593-597.	4.1	86
61	Internalization of basic fibroblast growth factor (bFGF) in cultured endothelial cells: Role of the low affinity heparin-like bFGF receptors. Journal of Cellular Physiology, 1993, 154, 152-161.	4.1	85
62	Distinct Role of 2-O-, N-, and 6-O-Sulfate Groups of Heparin in the Formation of the Ternary Complex with Basic Fibroblast Growth Factor and Soluble FGF Receptor-1. Biochemical and Biophysical Research Communications, 1994, 203, 450-458.	2.1	85
63	Human lymphoblastoid cells produce extracellular matrix-degrading enzymes and induce endothelial cell proliferation, migration, morphogenesis, and angiogenesis. International Journal of Clinical and Laboratory Research, 1998, 28, 55-68.	1.0	85
64	Undersulfated and Glycol-Split Heparins Endowed with Antiangiogenic Activity. Journal of Medicinal Chemistry, 2004, 47, 838-848.	6.4	80
65	The discovery of basic fibroblast growth factor/fibroblast growth factor-2 and its role in haematological malignancies. Cytokine and Growth Factor Reviews, 2007, 18, 327-334.	7.2	78
66	A six-amino acid deletion in basic fibroblast growth factor dissociates its mitogenic activity from its plasminogen activator-inducing capacity Proceedings of the National Academy of Sciences of the United States of America, 1991, 88, 2628-2632.	7.1	76
67	Role of soluble mediators in angiogenesis. European Journal of Cancer, 1996, 32, 2401-2412.	2.8	76
68	αvβ3 integrin engagement modulates cell adhesion, proliferation, and protease secretion in human lymphoid tumor cells. Experimental Hematology, 2001, 29, 993-1003.	0.4	76
69	Short Heparin Sequences Spaced by Glycol-Split Uronate Residues Are Antagonists of Fibroblast Growth Factor 2 and Angiogenesis Inhibitors. Biochemistry, 2002, 41, 10519-10528.	2.5	76
70	Anti-FGF2 approaches asÂaÂstrategy toÂcompensate resistance toÂanti-VEGF therapy: long-pentraxin 3Âas aÂnovel antiangiogenic FGF2-antagonist. European Cytokine Network, 2009, 20, 225-234.	2.0	76
71	In vitro and ex vivo retina angiogenesis assays. Angiogenesis, 2014, 17, 429-442.	7.2	76
72	Future applications of FGF/FGFR inhibitors in cancer. Expert Review of Anticancer Therapy, 2018, 18, 861-872.	2.4	76

#	Article	IF	CITATIONS
73	Biological and molecular properties of a new αvβ3/αvβ5 integrin antagonist. Molecular Cancer Therapeutics, 2005, 4, 1670-1680.	4.1	75
74	Purification from a human hepatoma cell line of a basic fibroblast growth factor-like molecule that stimulates capillary endothelial cell plasminogen activator production, DNA synthesis, and migration. Molecular and Cellular Biology, 1986, 6, 4060-4066.	2.3	74
75	Fibroblast Growth Factor-2 Antagonist Activity and Angiostatic Capacity of Sulfated Escherichia coli K5 Polysaccharide Derivatives. Journal of Biological Chemistry, 2001, 276, 37900-37908.	3.4	73
76	The potential of fibroblast growth factor/fibroblast growth factor receptor signaling as a therapeutic target in tumor angiogenesis. Expert Opinion on Therapeutic Targets, 2015, 19, 1361-1377.	3.4	72
77	Non-peptidic Thrombospondin-1 Mimics as Fibroblast Growth Factor-2 Inhibitors. Journal of Biological Chemistry, 2010, 285, 8733-8742.	3.4	70
78	The natural compound n-butylidenephthalide derived from the volatile oil of Radix Angelica sinensis inhibits angiogenesis in vitro and in vivo. Angiogenesis, 2011, 14, 187-197.	7.2	69
79	Long Pentraxin 3/Tumor Necrosis Factor-Stimulated Gene-6 Interaction. Arteriosclerosis, Thrombosis, and Vascular Biology, 2012, 32, 696-703.	2.4	69
80	Blocking the FGF/FGFR system as a â;¿two-compartmentâ;¿ antiangiogenic/antitumor approach in cancer therapy. Pharmacological Research, 2016, 107, 172-185.	7.1	69
81	Long Pentraxin-3 Inhibits Epithelial–Mesenchymal Transition in Melanoma Cells. Molecular Cancer Therapeutics, 2013, 12, 2760-2771.	4.1	68
82	Pentosan Polysulfate as an Inhibitor of Extracellular HIV-1 Tat. Journal of Biological Chemistry, 2001, 276, 22420-22425.	3.4	67
83	Fibroblast growth factor-2 binding to the thrombospondin-1 type III repeats, a novel antiangiogenic domain. International Journal of Biochemistry and Cell Biology, 2008, 40, 700-709.	2.8	67
84	Interaction of high-molecular-weight basic fibroblast growth factor with endothelium: Biological activity and intracellular fate of human recombinant Mr 24,000 bFGF. Journal of Cellular Physiology, 1994, 161, 149-159.	4.1	66
85	Cell-Mediated Delivery of Fibroblast Growth Factor-2 and Vascular Endothelial Growth Factor onto the Chick Chorioallantoic Membrane: Endothelial Fenestration and Angiogenesis. Journal of Vascular Research, 2001, 38, 389-397.	1.4	66
86	A proâ€inflammatory signature mediates FGF2â€induced angiogenesis. Journal of Cellular and Molecular Medicine, 2009, 13, 2083-2108.	3.6	66
87	Interaction of Fibroblast Growth Factor-2 (FGF-2) with Free Gangliosides: Biochemical Characterization and Biological Consequences in Endothelial Cell Cultures. Molecular Biology of the Cell, 1999, 10, 313-327.	2.1	65
88	Long pentraxin 3: A novel multifaceted player in cancer. Biochimica Et Biophysica Acta: Reviews on Cancer, 2018, 1869, 53-63.	7.4	65
89	Basic fibroblast growth factor requires a long-lasting activation of protein kinase C to induce cell proliferation in transformed fetal bovine aortic endothelial cells Molecular Biology of the Cell, 1991, 2, 719-726.	6.5	64
90	Long pentraxinâ€3 as an epithelial–stromal fibroblast growth factorâ€ŧargeting inhibitor in prostate cancer. Journal of Pathology, 2013, 230, 228-238.	4.5	64

#	Article	IF	CITATIONS
91	Nuclear localization of endogenous basic fibroblast growth factor in cultured endothelial cells. Experimental Cell Research, 1991, 192, 505-510.	2.6	62
92	Heparan Sulfate Proteoglycans Mediate the Angiogenic Activity of the Vascular Endothelial Growth Factor Receptor-2 Agonist Gremlin. Arteriosclerosis, Thrombosis, and Vascular Biology, 2011, 31, e116-27.	2.4	62
93	Biological activity of substrate-bound basic fibroblast growth factor (FGF2): recruitment of FGF receptor-1 in endothelial cell adhesion contacts. Oncogene, 2002, 21, 3889-3897.	5.9	61
94	Heparin Octasaccharides Inhibit Angiogenesis In vivo. Clinical Cancer Research, 2005, 11, 8172-8179.	7.0	61
95	EmbryonicFetal Hb switch in humans: studies on erythroid bursts generated by embryonic progenitors from yolk sac and liver Proceedings of the National Academy of Sciences of the United States of America, 1984, 81, 2416-2420.	7.1	60
96	Zebrafish embryo, a tool to study tumor angiogenesis. International Journal of Developmental Biology, 2011, 55, 505-509.	0.6	60
97	Long Pentraxin-3 Modulates the Angiogenic Activity of Fibroblast Growth Factor-2. Frontiers in Immunology, 2018, 9, 2327.	4.8	60
98	Fibroblast growth factor 2â€induced angiogenesis in zebrafish: the zebrafish yolk membrane (ZFYM) angiogenesis assay. Journal of Cellular and Molecular Medicine, 2009, 13, 2061-2068.	3.6	58
99	In vivo angiogenic activity of urokinase: role of endogenous fibroblast growth factor-2. Journal of Cell Science, 1999, 112, 4213-4221.	2.0	58
100	Purification of basic fibroblast growth factor from rat brain: Identification of a Mr 22,000 immunoreactive form. Biochemical and Biophysical Research Communications, 1988, 155, 1161-1172.	2.1	57
101	Multiple forms of an angiogenesis factor: basic fibroblast growth factor. Biochimie, 1988, 70, 83-87.	2.6	54
102	Paracrine and autocrine effects of fibroblast growth factor-4 in endothelial cells. Oncogene, 2001, 20, 2655-2663.	5.9	53
103	Overexpression of cytosolic sialidase Neu2 induces myoblast differentiation in C2C12 cells. FEBS Letters, 2003, 547, 183-188.	2.8	53
104	Long Pentraxin-3 Inhibits FGF8b-Dependent Angiogenesis and Growth of Steroid Hormone–Regulated Tumors. Molecular Cancer Therapeutics, 2011, 10, 1600-1610.	4.1	53
105	Biochemical bases of the interaction of human basic fibroblast growth factor with glycosaminoglycans. New insights from trypsin digestion studies. FEBS Journal, 1993, 214, 51-58.	0.2	52
106	Fibroblast Growth Factors and Their Receptors in Hematopoiesis and Hematological Tumors. Journal of Hematotherapy and Stem Cell Research, 2002, 11, 19-32.	1.8	52
107	Recombinant human erythropoietin induces intussusceptive microvascular growth in vivo. Leukemia, 2004, 18, 331-336.	7.2	52
108	Biotechnological Engineering of Heparin/Heparan Sulphate: A Novel Area of Multi-Target Drug Discovery. Current Pharmaceutical Design, 2005, 11, 2489-2499.	1.9	52

#	Article	IF	CITATIONS
109	Basic fibroblast growth factor: Production, mitogenic response, and post-receptor signal transduction in cultured normal and transformed fetal bovine aortic endothelial cells. Journal of Cellular Physiology, 1989, 141, 517-526.	4.1	50
110	Chemically sulfatedEscherichia coliK5 polysaccharide derivatives as extracellular HIV-1 Tat protein antagonists. FEBS Letters, 2004, 568, 171-177.	2.8	50
111	Human iPSC modelling of a familial form of atrial fibrillation reveals a gain of function of If and ICaL in patient-derived cardiomyocytes. Cardiovascular Research, 2020, 116, 1147-1160.	3.8	50
112	Basic Fibroblast Growth Factor in Ovulatory Cycle and Postmenopausal Human Endometrium. Growth Factors, 1990, 3, 299-307.	1.7	49
113	Undersulfated, low-molecular-weight glycol-split heparin as an antiangiogenic VEGF antagonist. Glycobiology, 2004, 15, 1C-6C.	2.5	48
114	αvβ3-integrin-dependent activation of focal adhesion kinase mediates NF-κB activation and motogenic activity by HIV-1 Tat in endothelial cells. Journal of Cell Science, 2005, 118, 3949-3958.	2.0	47
115	Purine analogue 6-methylmercaptopurine riboside inhibits early and late phases of the angiogenesis process. Cancer Research, 1999, 59, 2417-24.	0.9	47
116	Fibroblast growth factor 2â€antagonist activity of a longâ€pentraxin 3â€derived antiâ€angiogenic pentapeptide. Journal of Cellular and Molecular Medicine, 2010, 14, 2109-2121.	3.6	46
117	Zebrafish embryo as a tool to study tumor/endothelial cell cross-talk. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2013, 1832, 1371-1377.	3.8	45
118	Cyclic Adenosine Monophosphate-Response Element–Binding Protein Mediates the Proangiogenic or Proinflammatory Activity of Gremlin. Arteriosclerosis, Thrombosis, and Vascular Biology, 2014, 34, 136-145.	2.4	45
119	Expression of basic fibroblast growth factor and its receptors in human fetal microglia cells. International Journal of Developmental Neuroscience, 1995, 13, 29-39.	1.6	44
120	Thrombospondin-1 inhibits Kaposi's sarcoma (KS) cell and HIV-1 Tat-induced angiogenesis and is poorly expressed in KS lesions. , 1999, 188, 76-81.		44
121	Integrin αVβ3as a Target for Blocking HIV-1 Tat-Induced Endothelial Cell Activation In Vitro and Angiogenesis In Vivo. Arteriosclerosis, Thrombosis, and Vascular Biology, 2005, 25, 2315-2320.	2.4	44
122	Extracellular Angiogenic Growth Factor Interactions: An Angiogenesis Interactome Survey. Endothelium: Journal of Endothelial Cell Research, 2006, 13, 93-111.	1.7	43
123	Transcriptional and posttranscriptional regulation of urokinase-type plasminogen activator expression in endothelial cells by basic fibroblast growth factor. Journal of Cellular Physiology, 1995, 162, 400-409.	4.1	42
124	Promotion of tumour metastases and induction of angiogenesis by native HIV-1 Tat protein from BK virus/tat transgenic mice. Aids, 1996, 10, 701-710.	2.2	42
125	HIV-1 Tat and heparan sulfate proteoglycan interaction: a novel mechanism of lymphocyte adhesion and migration across the endothelium. Blood, 2009, 114, 3335-3342.	1.4	42
126	Involvement of $\hat{1}\pm v \hat{1}^2 3$ integrin in gremlin-induced angiogenesis. Angiogenesis, 2013, 16, 235-243.	7.2	42

#	Article	IF	CITATIONS
127	SIGMAR1 Regulates Membrane Electrical Activity in Response to Extracellular Matrix Stimulation to Drive Cancer Cell Invasiveness. Cancer Research, 2016, 76, 607-618.	0.9	42
128	Modulation of tumor angiogenesis by conditional expression of fibroblast growth factor-2 affects early but not established tumors. Cancer Research, 2001, 61, 309-17.	0.9	42
129	Characterization of a Mr 25,000 basic fibroblast growth factor form in adult, regenerating, and fetal rat liver. Biochemical and Biophysical Research Communications, 1989, 164, 1182-1189.	2.1	41
130	The COOH-Terminal Peptide of Platelet Factor-4 Variant (CXCL4L1/PF-4var47-70) Strongly Inhibits Angiogenesis and Suppresses B16 Melanoma Growth <i>In vivo</i> . Molecular Cancer Research, 2010, 8, 322-334.	3.4	41
131	FGF Trapping Inhibits Multiple Myeloma Growth through c-Myc Degradation–Induced Mitochondrial Oxidative Stress. Cancer Research, 2020, 80, 2340-2354.	0.9	41
132	Different effects of mucosal, bovine lung and chemically modified heparin on selected biological properties of basic fibroblast growth factor. Biochemical Journal, 1994, 303, 583-590.	3.7	40
133	Activation of Endothelial Cell Mitogen Activated Protein Kinase ERK <sub>1/2</sub> by Extracellular HIV-1 Tat Protein. Endothelium: Journal of Endothelial Cell Research, 2001, 8, 65-74.	1.7	40
134	αvβ3 Integrin-dependent antiangiogenic activity of resveratrol stereoisomers. Molecular Cancer Therapeutics, 2008, 7, 3761-3770.	4.1	40
135	Direct and Allosteric Inhibition of the FGF2/HSPGs/FGFR1 Ternary Complex Formation by an Antiangiogenic, Thrombospondin-1-Mimic Small Molecule. PLoS ONE, 2012, 7, e36990.	2.5	40
136	Inhibition of angiogenesis in rats by IL-1 receptor antagonist and selected cytokine antibodies. Inflammation, 1994, 18, 45-58.	3.8	39
137	A distinct basic fibroblast growth factor (FGF-2)/FGF receptor interaction distinguishes urokinase-type plasminogen activator induction from mitogenicity in endothelial cells Molecular Biology of the Cell, 1996, 7, 369-381.	2.1	39
138	Role of endothelial cell extracellular signal-regulated kinase1/2 in urokinase-type plasminogen activator upregulation and in vitro angiogenesis by fibroblast growth factor-2. Journal of Cell Science, 1999, 112, 2597-2606.	2.0	39
139	Role of fibroblast growth factorâ€⊋ in human brain: a focus on development. International Journal of Developmental Neuroscience, 2000, 18, 271-279.	1.6	38
140	Calcitonin receptor-like receptor guides arterial differentiation in zebrafish. Blood, 2008, 111, 4965-4972.	1.4	38
141	Matrigel plug assay: evaluation of the angiogenic response by reverse transcription-quantitative PCR. Angiogenesis, 2013, 16, 469-477.	7.2	38
142	Angiopoietin-1 mediates the proangiogenic activity of the bone morphogenic protein antagonist Drm. Blood, 2008, 112, 1154-1157.	1.4	37
143	Anti-angiogenic activity of the flavonoid precursor 4-hydroxychalcone. European Journal of Pharmacology, 2012, 691, 125-133.	3.5	37
144	Dendritic cells in inflammatory angiogenesis and lymphangiogenesis. Current Opinion in Immunology, 2018, 53, 180-186.	5.5	37

#	Article	IF	CITATIONS
145	Angiogenesis-Inflammation Cross Talk in Diabetic Retinopathy: Novel Insights From the Chick Embryo Chorioallantoic Membrane/Human Vitreous Platform. Frontiers in Immunology, 2020, 11, 581288.	4.8	37
146	The FGF/FGFR system in the physiopathology of the prostate gland. Physiological Reviews, 2021, 101, 569-610.	28.8	37
147	Brain angioarchitecture and intussusceptive microvascular growth in a murine model of Krabbe disease. Angiogenesis, 2015, 18, 499-510.	7.2	36
148	The nanostructured secretome. Biomaterials Science, 2020, 8, 39-63.	5.4	36
149	Impact of fibroblast growth factor-2 on tumor microvascular architecture. A tridimensional morphometric study. American Journal of Pathology, 1998, 152, 1607-16.	3.8	36
150	Alterations of blood vessel development by endothelial cells overexpressing fibroblast growth factor-2. , 1999, 189, 590-599.		35
151	Antiangiogenic Activity of Semisynthetic Biotechnological Heparins. Arteriosclerosis, Thrombosis, and Vascular Biology, 2005, 25, 71-76.	2.4	35
152	Zebrafish ( Danio rerio ) embryo as a platform for the identification of novel angiogenesis inhibitors of retinal vascular diseases. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2016, 1862, 1291-1296.	3.8	35
153	High molecular weight immunoreactive basic fibroblast growth factor-like proteins in rat pituitary and brain. Neuroscience Letters, 1988, 90, 308-313.	2.1	34
154	Pentraxin 3 (PTX3) inhibits plasma cell/stromal cell crossâ€ŧalk in the bone marrow of multiple myeloma patients. Journal of Pathology, 2013, 229, 87-98.	4.5	34
155	Monomeric gremlin is a novel vascular endothelial growth factor receptor-2 antagonist. Oncotarget, 2016, 7, 35353-35368.	1.8	34
156	Modulation of plasminogen activator activity in human endometrial adenocarcinoma cells by basic fibroblast growth factor and transforming growth factor beta. Cancer Research, 1988, 48, 6384-9.	0.9	34
157	Basic fibroblast growth factor in human pheochromocytoma: A biochemical and immunohistochemical study. International Journal of Cancer, 1993, 53, 5-10.	5.1	33
158	Modulation of Angiogenesis by a Tetrameric Tripeptide That Antagonizes Vascular Endothelial Growth Factor Receptor 1. Journal of Biological Chemistry, 2008, 283, 34250-34259.	3.4	33
159	Fibroblast Growth Factor-2 Antagonist and Antiangiogenic Activity of Long-Pentraxin 3-Derived Synthetic Peptides. Current Pharmaceutical Design, 2009, 15, 3577-3589.	1.9	33
160	TR-644 a novel potent tubulin binding agent induces impairment of endothelial cells function and inhibits angiogenesis. Angiogenesis, 2013, 16, 647-662.	7.2	33
161	Inflammation and N-formyl peptide receptors mediate the angiogenic activity of human vitreous humour in proliferative diabetic retinopathy. Diabetologia, 2017, 60, 719-728.	6.3	33
162	Contribution of vascular endothelial growth factor receptor-2 sialylation to the process of angiogenesis. Oncogene, 2017, 36, 6531-6541.	5.9	33

#	Article	IF	CITATIONS
163	VEGFR2 activation mediates the pro-angiogenic activity of BMP4. Angiogenesis, 2019, 22, 521-533.	7.2	33
164	Inhibition of fibroblast growth factor-2-induced vascular tumor formation by the acyclic nucleoside phosphonate cidofovir. Cancer Research, 2001, 61, 5057-64.	0.9	33
165	Biologically active synthetic fragments of human basic fibroblast growth factor (bFGF): Identification of two Asp-Gly-Arg-Containing domains involved in the mitogenic activity of bFGF in endothelial cells. Journal of Cellular Physiology, 1991, 149, 512-524.	4.1	32
166	Inhibition of angiogenesis by β-galactosylceramidase deficiency in globoid cell leukodystrophy. Brain, 2013, 136, 2859-2875.	7.6	32
167	Synthesis of Urokinase-Type Plasminogen Activator and of Type- 1 Plasminogen Activator Inhibitor in Neuronal Cultures of Human Fetal Brain: Stimulation by Phorbol Ester. Journal of Neurochemistry, 1990, 55, 1647-1654.	3.9	31
168	Structure-function relationship of basic fibroblast growth factor: Site-directed mutagenesis of a putative heparin-binding and receptor-binding region. Biochemical and Biophysical Research Communications, 1992, 185, 1098-1107.	2.1	31
169	Antiangiogenic Effectiveness of the Urokinase Receptor-Derived Peptide UPARANT in a Model of Oxygen-Induced Retinopathy. , 2015, 56, 2392.		31
170	Fibroblast growth factor modulates mast cell recruitment in a murine model of prostate cancer. Oncotarget, 2017, 8, 82583-82592.	1.8	31
171	Gene expression profile in fibroblast growth factor 2-transformed endothelial cells. Oncogene, 2002, 21, 2433-2440.	5.9	30
172	Thrombospondin-1 as a Paradigm for the Development of Antiangiogenic Agents Endowed with Multiple Mechanisms of Action. Pharmaceuticals, 2010, 3, 1241-1278.	3.8	30
173	A novel exÂvivo murine retina angiogenesis (EMRA) assay. Experimental Eye Research, 2013, 112, 51-56.	2.6	30
174	Growth advantage and vascularization induced by basic fibroblast growth factor overexpression in endometrial HEC-1-B cells: an export-dependent mechanism of action. Cancer Research, 1995, 55, 4729-38.	0.9	30
175	Differential expression of fibroblast growth factor receptors by human neurones, astrocytes, and microglia. NeuroReport, 1994, 6, 197-200.	1.2	29
176	Endogenous and exogenous fibroblast growth factor-2 modulate wound healing in the chick embryo chorioallantoic membrane. Angiogenesis, 1999, 3, 89-95.	7.2	29
177	The role of fibroblast growth factor-2 in the vascularization of the chick embryo chorioallantoic membrane. Journal of Cellular and Molecular Medicine, 2002, 6, 439-446.	3.6	29
178	Sphingosine-1-Phosphate Receptor-1 Controls Venous Endothelial Barrier Integrity in Zebrafish. Arteriosclerosis, Thrombosis, and Vascular Biology, 2012, 32, e104-16.	2.4	29
179	Synthesis, Structural Elucidation, and Biological Evaluation of NSC12, an Orally Available Fibroblast Growth Factor (FGF) Ligand Trap for the Treatment of FGF-Dependent Lung Tumors. Journal of Medicinal Chemistry, 2016, 59, 4651-4663.	6.4	29
180	The 140-kilodalton antiangiogenic fragment of thrombospondin-1 binds to basic fibroblast growth factor. Cell Growth & Differentiation: the Molecular Biology Journal of the American Association for Cancer Research, 1997, 8, 471-9.	0.8	29

#	Article	IF	CITATIONS
181	Inhibition of inducible nitric oxide synthase mRNA expression by basic fibroblast growth factor in human microglial cells. Neuroscience Letters, 1995, 195, 45-48.	2.1	28
182	Clinical studies with angiogenesis inhibitors: Biological rationale and challenges for their evaluation. Annals of Oncology, 1996, 7, 441-444.	1.2	28
183	Antiangiogenic Activity of a Neutralizing Human Single-Chain Antibody Fragment against Fibroblast Growth Factor Receptor 1. Molecular Cancer Therapeutics, 2010, 9, 3244-3253.	4.1	28
184	Different Tyrosine Autophosphorylation Requirements in Fibroblast Growth Factor Receptor-1 Mediate Urokinase-Type Plasminogen Activator Induction and Mitogenesis. Molecular Biology of the Cell, 1999, 10, 23-33.	2.1	27
185	Thrombospondinâ€1/HIVâ€1 Tat protein interaction: modulation of the biological activity of extracellular Tat. FASEB Journal, 2000, 14, 1917-1930.	0.5	27
186	Anti-angiogenic activity of the purine analog 6-thioguanine. Leukemia, 2002, 16, 1490-1499.	7.2	27
187	Osteopontin Overexpression Inhibits in Vitro Re-endothelialization via Integrin Engagement. Journal of Biological Chemistry, 2007, 282, 19676-19684.	3.4	27
188	N-tert-butyloxycarbonyl-Phe-Leu-Phe-Leu-Phe (BOC2) inhibits the angiogenic activity of heparin-binding growth factors. Angiogenesis, 2018, 21, 47-59.	7.2	27
189	A long pentraxin-3-derived pentapeptide for the therapy of FGF8b-driven steroid hormone-regulated cancers. Oncotarget, 2015, 6, 13790-13802.	1.8	27
190	Basic fibroblast growth factor in neuronal cultures of human fetal brain. Journal of Neuroscience Research, 1990, 27, 78-83.	2.9	26
191	Delivering cytokines at tumor site: The immunocytokine-conjugated anti-EDB-fibronectin antibody case. Immunobiology, 2009, 214, 800-810.	1.9	26
192	Molecular cloning and knockdown of galactocerebrosidase in zebrafish: New insights into the pathogenesis of Krabbe's disease. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2014, 1842, 665-675.	3.8	26
193	Angiogenic growth factors interactome and drug discovery: The contribution of surface plasmon resonance. Cytokine and Growth Factor Reviews, 2015, 26, 293-310.	7.2	26
194	Human placental tissue stimulates bovine capillary endothelial cell growth, migration and protease production. Bioscience Reports, 1985, 5, 783-790.	2.4	25
195	Endothelial cells overexpressing basic fibroblast growth factor (FGF-2) induce vascular tumors in immunodeficient mice. Angiogenesis, 1997, 1, 102-116.	7.2	25
196	Biosafe inertization of municipal solid waste incinerator residues by COSMOS technology. Journal of Hazardous Materials, 2014, 279, 311-321.	12.4	25
197	Characterization of a Mr 20,000 basic fibroblast growth factor-like protein secreted by normal and transformed fetal bovine aortic endothelial cells. Experimental Cell Research, 1990, 186, 354-361.	2.6	24
198	Role of Nanomechanics in Canonical and Noncanonical Pro-angiogenic Ligand/VEGF Receptor-2 Activation. Journal of the American Chemical Society, 2012, 134, 14573-14579.	13.7	24

#	Article	IF	CITATIONS
199	Long Pentraxin 3-Mediated Fibroblast Growth Factor Trapping Impairs Fibrosarcoma Growth. Frontiers in Oncology, 2018, 8, 472.	2.8	24
200	Long Pentraxin-3 Follows and Modulates Bladder Cancer Progression. Cancers, 2019, 11, 1277.	3.7	24
201	Inhibition of the FGF/FGFR System Induces Apoptosis in Lung Cancer Cells via c-Myc Downregulation and Oxidative Stress. International Journal of Molecular Sciences, 2020, 21, 9376.	4.1	24
202	The NH2-Terminal Extension of High Molecular Weight Forms of Basic Fibroblast Growth Factor (bFGF) is not Essential for the Binding of bFGF to Nuclear Chromatin in Transfected NIH 3T3 Cells. Growth Factors, 1993, 8, 49-60.	1.7	23
203	Angiostatic, tumor inflammatory and anti-tumor effects of CXCL447-70 and CXCL4L147–70 in an EGF-dependent breast cancer model. Oncotarget, 2014, 5, 10916-10933.	1.8	23
204	Estro-Progestinic Replacement Therapy Modulates the Levels of Basic Fibroblast Growth Factor (bFGF) in Postmenopausal Endometrium. Gynecologic Oncology, 1993, 48, 88-93.	1.4	22
205	Basic fibroblast growth factor overexpression in endothelial cells: an autocrine mechanism for angiogenesis and angioproliferative diseases. Cell Growth & Differentiation: the Molecular Biology Journal of the American Association for Cancer Research, 1996, 7, 147-60.	0.8	22
206	The Thymidine Phosphorylase Inhibitor 5â€2- <i>O</i> -Tritylinosine (KIN59) Is an Antiangiogenic Multitarget Fibroblast Growth Factor-2 Antagonist. Molecular Cancer Therapeutics, 2012, 11, 817-829.	4.1	21
207	Therapeutic Potential of Anti-Angiogenic Multitarget <i>N,O</i> -Sulfated <i>E. Coli</i> K5 Polysaccharide in Diabetic Retinopathy. Diabetes, 2015, 64, 2581-2592.	0.6	21
208	HIV-1 Tat protein: A target for the development of anti-AIDS therapies. Drugs of the Future, 2002, 27, 481.	0.1	21
209	Decrease of the activity of the mixed function oxidase system in regenerating rat liver: An alternative explanation. Biochemical and Biophysical Research Communications, 1980, 95, 829-834.	2.1	19
210	Developmentally regulated expression and localization of fibroblast growth factor receptors in the human muscle. , 1998, 211, 362-373.		19
211	Total reflection Xâ€Ray fluorescence spectroscopy to study Pb and Zn accumulation in zebrafish embryos. X-Ray Spectrometry, 2015, 44, 124-128.	1.4	19
212	Liver tumors induced by a new beta-adrenoreceptor blocking agent in female rats. Journal of the National Cancer Institute, 1982, 68, 669-72.	6.3	19
213	Up-regulation of urokinase-type plasminogen activator in squamous cell carcinoma of human larynx. British Journal of Cancer, 1996, 74, 1168-1174.	6.4	18
214	The Autocrine FGF/FGFR System in both Skin and Uveal Melanoma: FGF Trapping as a Possible Therapeutic Approach. Cancers, 2019, 11, 1305.	3.7	18
215	Zebrafish disease models in hematology: Highlights on biological and translational impact. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2019, 1865, 620-633.	3.8	18
216	VEGF-Independent Activation of Müller Cells by the Vitreous from Proliferative Diabetic Retinopathy Patients. International Journal of Molecular Sciences, 2021, 22, 2179.	4.1	18

#	Article	IF	CITATIONS
217	Subcellular Localization and Biological Activity of Mr 18,000 Basic Fibroblast Growth Factor: Site-Directed Mutagenesis of a Putative Nuclear Translocation Sequence. Growth Factors, 1993, 9, 269-278.	1.7	17
218	Urokinase-Type Plasminogen Activator Overexpression Enhances the Invasive Capacity of Endothelial Cells. Microvascular Research, 1997, 53, 254-260.	2.5	17
219	Exploiting Surface Plasmon Resonance (SPR) Technology for the Identification of Fibroblast Growth Factor-2 (FGF2) Antagonists Endowed with Antiangiogenic Activity. Sensors, 2009, 9, 6471-6503.	3.8	17
220	Impact of VEGFâ€dependent tumour microâ€environment on EDB fibronectin expression by subcutaneous human tumour xenografts in nude mice. Journal of Pathology, 2009, 219, 455-462.	4.5	17
221	Evaluation of the tumor-promoting activity of two β-adrenoreceptor blocking agents, propranolol and atenolol, in liver of Fischer 344 rats. Carcinogenesis, 1994, 15, 2531-2539.	2.8	16
222	Characterization of the Effects of Two Polysulfonated Distamycin A Derivatives, PNU145156E and PNU153429, on HIV Type 1 Tat Protein. AIDS Research and Human Retroviruses, 1998, 14, 1561-1571.	1.1	16
223	l² <sub>3</sub> Integrin Promotes Long-Lasting Activation and Polarization of Vascular Endothelial Growth Factor Receptor 2 by Immobilized Ligand. Arteriosclerosis, Thrombosis, and Vascular Biology, 2015, 35, 2161-2171.	2.4	16
224	3D endothelial cell spheroid/human vitreous humor assay for the characterization of anti-angiogenic inhibitors for the treatment of proliferative diabetic retinopathy. Angiogenesis, 2017, 20, 629-640.	7.2	16
225	Human Erythropoietin Induces a Pro-Angiogenic Phenotype in Cultured Endothelial Cells and Stimulates Neovascularization In Vivo. Blood, 1999, 93, 2627-2636.	1.4	16
226	In vitro and in vivo DNA damage of male and female rat liver nuclei by oncogenic and nononcogenic beta blockers. Journal of the National Cancer Institute, 1983, 70, 747-52.	6.3	16
227	Elucidation of a signaling pathway induced by FGF-2 leading to uPA gene expression in NIH 3T3 fibroblasts. Cell Growth & Differentiation: the Molecular Biology Journal of the American Association for Cancer Research, 1995, 6, 1009-17.	0.8	16
228	Noncompetitive, Chemokine-mediated Inhibition of Basic Fibroblast Growth Factor-induced Endothelial Cell Proliferation. Journal of Biological Chemistry, 1998, 273, 7911-7919.	3.4	15
229	Arabinose-derived bicyclic amino acids: synthesis, conformational analysis and construction of an αvβ3-selective RGD peptide. Journal of the Chemical Society, Perkin Transactions 1, 2002, , 638-644.	1.3	15
230	Substrate-Immobilized HIV-1 Tat Drives VEGFR2/α <sub>v</sub> β <sub>3</sub> –Integrin Complex Formation and Polarization in Endothelial Cells. Arteriosclerosis, Thrombosis, and Vascular Biology, 2012, 32, e25-34.	2.4	15
231	Caffeine Inhibits Direct and Indirect Angiogenesis in Zebrafish Embryos. International Journal of Molecular Sciences, 2021, 22, 4856.	4.1	15
232	Claudin3 is localized outside the tight junctions in human carcinomas. Oncotarget, 2018, 9, 18446-18453.	1.8	15
233	Nanoliter contact angle probes tumor angiogenic ligand–receptor protein interactions. Biosensors and Bioelectronics, 2010, 26, 1571-1575.	10.1	14
234	Endothelial cell dysfunction in globoid cell leukodystrophy. Journal of Neuroscience Research, 2016, 94, 1359-1367.	2.9	14

#	Article	IF	CITATIONS
235	PTX3 Modulates Neovascularization and Immune Inflammatory Infiltrate in a Murine Model of Fibrosarcoma. International Journal of Molecular Sciences, 2019, 20, 4599.	4.1	14
236	Role of basic fibroblast growth factor in the formation of the capillary plexus in the chick embryo chorioallantoic membrane. An in situ hybridization, immunohistochemical and ultrastructural study. Journal of Submicroscopic Cytology and Pathology, 1998, 30, 127-36.	0.3	14
237	Basic fibroblast growth factor modulates in vitro differentiation of human fetal microglia. NeuroReport, 1996, 7, 2813-2818.	1.2	13
238	Basic Fibroblast Growth Factor-Induced Angiogenesis in the Chick Embryo Chorioallantoic Membrane: An Electron Microscopy Study. Microvascular Research, 1997, 53, 187-190.	2.5	13
239	FGF2-induced upregulation of DNA polymerase-δp12 subunit in endothelial cells. Oncogene, 2005, 24, 1117-1121.	5.9	13
240	Vascular Endothelial Growth Factor in the Vitreous of Proliferative Diabetic Retinopathy Patients: Chasing a Hiding Prey?. Diabetes Care, 2019, 42, e105-e106.	8.6	13
241	Regulated expression pattern of gremlin during zebrafish development. Gene Expression Patterns, 2005, 5, 539-544.	0.8	12
242	β-Galactosylceramidase Promotes Melanoma Growth via Modulation of Ceramide Metabolism. Cancer Research, 2020, 80, 5011-5023.	0.9	12
243	Induction of plasminogen activator activity by phorbol ester in transformed fetal bovine aortic endothelial cells. Possible independence from protein kinase C. Biochemical and Biophysical Research Communications, 1989, 160, 682-691.	2.1	11
244	Fibroblast growth factor receptorâ€1 phosphorylation requirement for cardiomyocyte differentiation in murine embryonic stem cells. Journal of Cellular and Molecular Medicine, 2009, 13, 1489-1498.	3.6	11
245	The adaptor protein p66shc is a positive regulator in the angiogenic response induced by hypoxic T cells. Journal of Leukocyte Biology, 2009, 87, 365-369.	3.3	11
246	Ascorbic acid rescues cardiomyocyte development in Fgfr1â^'/â^' murine embryonic stem cells. Biochimica Et Biophysica Acta - Molecular Cell Research, 2013, 1833, 140-147.	4.1	11
247	COSMOS-rice technology abrogates the biotoxic effects of municipal solid waste incinerator residues. Environmental Pollution, 2016, 214, 713-721.	7.5	11
248	Gene expression analysis identifies two distinct molecular clusters of idiopatic epiretinal membranes. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2020, 1866, 165938.	3.8	11
249	Endogenous Long Pentraxin 3 Exerts a Protective Role in a Murine Model of Pulmonary Fibrosis. Frontiers in Immunology, 2021, 12, 617671.	4.8	11
250	Zebrafish Embryo Intersegmental Vessels: A Tool for Investigating Sprouting Angiogenesis. Methods in Molecular Biology, 2015, 1214, 173-184.	0.9	11
251	U94 of human herpesvirus 6 down-modulates Src, promotes a partial mesenchymal-to-epithelial transition and inhibits tumor cell growth, invasion and metastasis. Oncotarget, 2017, 8, 44533-44549.	1.8	11
252	Immunoreactive Basic Fibroblast Growth Factor-Like Proteins in Chromaffin Granules. Journal of Neurochemistry, 1991, 56, 1087-1088.	3.9	10

#	Article	IF	CITATIONS
253	The broad-spectrum anti-DNA virus agent cidofovir inhibits lung metastasis of virus-independent, FGF2-driven tumors. Oncotarget, 2015, 6, 4633-4648.	1.8	10
254	Circulating microRNAs and Their Role in Multiple Myeloma. Non-coding RNA, 2019, 5, 37.	2.6	10
255	Modeling Acquired Resistance to the Second-Generation Androgen Receptor Antagonist Enzalutamide in the TRAMP Model of Prostate Cancer. Cancer Research, 2020, 80, 1564-1577.	0.9	10
256	Specific targeting of the KRAS mutational landscape in myeloma as a tool to unveil the elicited antitumor activity. Blood, 2021, 138, 1705-1720.	1.4	10
257	New Aspects of Blood Vessel Growth: Tumor and Tissue-Derived Angiogenesis Factors. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 1988, 18, 6-17.	0.3	9
258	Atypical Chemokine Receptor 3 Generates Guidance Cues for CXCL12-Mediated Endothelial Cell Migration. Frontiers in Immunology, 2019, 10, 1092.	4.8	9
259	Targeting the Endothelin-1 Receptors Curtails Tumor Growth and Angiogenesis in Multiple Myeloma. Frontiers in Oncology, 2020, 10, 600025.	2.8	9
260	Purification and biological activities of an angiogenesis factor from human placenta. Anticancer Research, 1986, 6, 861-3.	1.1	9
261	Role of endothelial cell extracellular signal-regulated kinase1/2 in urokinase-type plasminogen activator upregulation and in vitro angiogenesis by fibroblast growth factor-2. Journal of Cell Science, 1999, 112 ( Pt 15), 2597-606.	2.0	9
262	Upregulation of urokinase-type plasminogen activator by endogenous and exogenous HIV-1 Tat protein in tumour cell lines derived from BK virus/tat-transgenic mice. Aids, 1997, 11, 727-736.	2.2	8
263	d-Peptide analogues of Boc-Phe-Leu-Phe-Leu-Phe-COOH induce neovascularization via endothelial N-formyl peptide receptor 3. Angiogenesis, 2020, 23, 357-369.	7.2	8
264	Expression of activated VEGFR2 by R1051Q mutation alters the energy metabolism of Sk-Mel-31 melanoma cells by increasing glutamine dependence. Cancer Letters, 2021, 507, 80-88.	7.2	8
265	Examining New Models for the Study of Autocrine and Paracrine Mechanisms of Angiogenesis Through FGF2-Transfected Endothelial and Tumour Cells. Advances in Experimental Medicine and Biology, 2000, 476, 7-34.	1.6	8
266	Synthetic Site-Selectively Mono-6-O-Sulfated Heparan Sulfate Dodecasaccharide Shows Anti-Angiogenic Properties In Vitro and Sensitizes Tumors to Cisplatin In Vivo. PLoS ONE, 2016, 11, e0159739.	2.5	8
267	Basic fibroblast growth factor bound to cell substrate promotes cell adhesion, proliferation, and protease production in cultured endothelial cells. Exs, 1992, 61, 205-209.	1.4	8
268	FGFR blockade by pemigatinib treats naÃ⁻ve and castration resistant prostate cancer. Cancer Letters, 2022, 526, 217-224.	7.2	8
269	Quantification of damage to striated muscle after normothermic or hypothermic ischemia. Clinical Chemistry, 1981, 27, 297-302.	3.2	8
270	Preferential induction of fetal versus embryonic globin chains in human leukemic cell lines. Leukemia Research, 1982, 6, 155-163.	0.8	7

#	Article	IF	CITATIONS
271	Antiangiogenesis by Chemotherapeutic Agents. Mini-Reviews in Medicinal Chemistry, 2005, 5, 313-317.	2.4	7
272	CEACAM1/VEGF crossâ€ŧalk during neuroblastic tumour differentiation. Journal of Pathology, 2007, 211, 541-549.	4.5	7
273	A novel variant of VEGFR2 identified by a pan-cancer screening of recurrent somatic mutations in the catalytic domain of tyrosine kinase receptors enhances tumor growth and metastasis. Cancer Letters, 2021, 496, 84-92.	7.2	7
274	Avian Reovirus P17 Suppresses Angiogenesis by Promoting DPP4 Secretion. Cells, 2021, 10, 259.	4.1	7
275	Tumor-initiating activity of the beta-blocker ZAMI 1305 in the liver of the female Wistar rat. Cancer Letters, 1984, 25, 1-11.	7.2	6
276	Inhibition of DNA and RNA Synthesis in Rat Liver Nuclei by Oncogenic and Non-oncogenic β-Blockers. Toxicologic Pathology, 1985, 13, 18-25.	1.8	6
277	Functional Domains of Basic Fibroblast Growth Factor: Possible Role of Asp-Gly-Arg Sequences in the Mitogenic Activity of bFGF. Annals of the New York Academy of Sciences, 1991, 638, 361-368.	3.8	6
278	Angiogenic phenotype induced by basic fibroblast growth factor transfection in brain microvascular endothelial cells. International Journal of Oncology, 1996, 8, 567-573.	3.3	6
279	Quantification of 3D Brain Microangioarchitectures in an Animal Model of Krabbe Disease. International Journal of Molecular Sciences, 2019, 20, 2384.	4.1	6
280	Long-Pentraxin 3 Affects Primary Cilium in Zebrafish Embryo and Cancer Cells via the FGF System. Cancers, 2020, 12, 1756.	3.7	6
281	Zebrafish embryo as an experimental model to study tumor angiogenesis. , 2020, , 129-145.		6
282	Pentraxin 3 Inhibits the Angiogenic Potential of Multiple Myeloma Cells. Cancers, 2021, 13, 2255.	3.7	6
283	Vitreous from idiopathic epiretinal membrane patients induces glial-to-mesenchymal transition in Müller cells. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2021, 1867, 166181.	3.8	6
284	Oncosuppressive and oncogenic activity of the sphingolipid-metabolizing enzyme β-galactosylceramidase. Biochimica Et Biophysica Acta: Reviews on Cancer, 2022, 1877, 188675.	7.4	6
285	In vitro inhibition of rat liver DNA polymerases $\hat{I}_{\pm}$ and $\hat{I}^2$ by $\hat{I}^2$ -blockers. Bioscience Reports, 1983, 3, 299-308.	2.4	5
286	Optical isomers of the hepatocarcinogenic β-blocker zami 1305: Influence on nucleic acids synthesis and DNA integrity. Chemico-Biological Interactions, 1984, 50, 77-86.	4.0	5
287	Age-dependent, seasonal and daily variations of the DNA damaging capacity of the hepatocarcinogen ZAMI 1305 in female rat liver. Cancer Letters, 1984, 23, 245-251.	7.2	5
288	Critical role of gonadal hormones on the genotoxic activity of the hepatocarcinogen DL-ZAMI 1305. Cancer Letters, 1987, 36, 253-261.	7.2	5

#	Article	IF	CITATIONS
289	Evaluation of the Biotoxicity of Tree Wood Ashes in Zebrafish Embryos. Zebrafish, 2016, 13, 449-455.	1.1	5
290	Vascular amounts and dispersion of caliber-classified vessels as key parameters to quantitate 3D micro-angioarchitectures in multiple myeloma experimental tumors. Scientific Reports, 2018, 8, 17520.	3.3	5
291	β-Galactosylceramidase Deficiency Causes Bone Marrow Vascular Defects in an Animal Model of Krabbe Disease. International Journal of Molecular Sciences, 2020, 21, 251.	4.1	5
292	β-Galactosylceramidase in cancer: friend or foe?. Trends in Cancer, 2021, 7, 974-977.	7.4	5
293	Inhibition in vitro of yeast DNA polymerase I activity by beta-blockers. Bioscience Reports, 1982, 2, 55-62.	2.4	4
294	Thyroid modifications in male and female rats treated with the hepatocarcinogen beta-blocker ZAMI 1305. Cancer Letters, 1983, 19, 293-299.	7.2	4
295	Halting the FGF/FGFR axis leads to antitumor activity in Waldenström macroglobulinemia by silencing MYD88. Blood, 2021, 137, 2495-2508.	1.4	4
296	Cross Talk between Haematopoiesis and Angiogenesis. Advances in Experimental Medicine and Biology, 2003, 522, 25-36.	1.6	4
297	The importance of the genomic landscape in Waldenström's Macroglobulinemia for targeted therapeutical interventions. Oncotarget, 2017, 8, 35435-35444.	1.8	4
298	Inhibition of protein synthesis in ischaemic liver from phenobarbitone-treated rat. Experientia, 1979, 35, 86-88.	1.2	3
299	Early liver alterations induced by the sex-dependent hepatocarcinogen Î <sup>2</sup> -blocker ZAMI 1305. Chemico-Biological Interactions, 1984, 52, 203-212.	4.0	3
300	Chemical structure and genotoxic activity of the hepatocarcinogenic beta-blocker DL-ZAMI 1305. Carcinogenesis, 1990, 11, 261-265.	2.8	3
301	A Mutant of Basic Fibroblast Growth Factor that Has Lost the Ability to Stimulate Plasminogen Activator Synthesis in Endothelial Cells. Annals of the New York Academy of Sciences, 1991, 638, 369-377.	3.8	3
302	In Situ DNA/Protein Interaction Assay to Visualize Transcriptional Factor Activation. Methods and Protocols, 2020, 3, 80.	2.0	3
303	Chemical modification of NSC12 leads to a specific FGF-trap with antitumor activity in multiple myeloma. European Journal of Medicinal Chemistry, 2021, 221, 113529.	5.5	3
304	Alterations of blood vessel development by endothelial cells overexpressing fibroblast growth factorâ€Â2. Journal of Pathology, 1999, 189, 590-599.	4.5	3
305	Activation of the tyrosine kinase receptor is not sufficient for the full biological activity of bFGF. Exs, 1992, 61, 101-106.	1.4	3
306	Production and Biochemical Characterization of Dimeric Recombinant Gremlin-1. International Journal of Molecular Sciences, 2022, 23, 1151.	4.1	3

#	Article	IF	CITATIONS
307	Liver growth after partial hepatectomy: Influence of phenobarbital administration. Experimental and Molecular Pathology, 1981, 34, 216-225.	2.1	2
308	Thyroid and Chemical Hepatocarcinogenesis: Further Insights from the Hepatocarcinogen Zami 1305. Toxicologic Pathology, 1984, 12, 49-55.	1.8	2
309	Nerve growth factor induces sphingomyelin accumulation in pheochromocytoma cells. FEBS Letters, 2000, 472, 143-147.	2.8	2
310	Pietro M. Gullino and Angiogenesis. Endothelium: Journal of Endothelial Cell Research, 2002, 9, 227-230.	1.7	2
311	Simultaneously characterization of tumoral angiogenesis and vasculogenesis in stem cell-derived teratomas. Experimental Cell Research, 2021, 400, 112490.	2.6	2
312	Fibroblast Growth Factor-2 in Angiogenesis. , 2008, , 77-88.		2
313	Specific Targeting of KRAS Using a Novel High-Affinity KRAS Antisense Oligonucleotide in Multiple Myeloma. Blood, 2019, 134, 3104-3104.	1.4	2
314	Basic Fibroblast Growth Factor Expression in Endothelial Cells: An Autocrine Role in Angiogenesis?. , 1996, , 61-72.		2
315	An Italian pioneer in the study of tumor angiogenesis. Haematologica, 2001, 86, 1234-5.	3.5	2
316	Further Studies on the Tumor-Initiating Activity of the Beta-Blocker DL-ZAMI 1305. Toxicologic Pathology, 1986, 14, 470-476.	1.8	1
317	The role of the endothelium in globoid-cell leukodystrophy: unexpected revelations. Future Neurology, 2014, 9, 127-130.	0.5	1
318	A tool for the quantification of radial neo-vessels in chick chorioallantoic membrane angiogenic assays. , 2015, 2015, 763-6.		1
319	Editorial overview: Lymphatic vessels: More than a draining pipeline. Current Opinion in Immunology, 2018, 53, vii-ix.	5.5	1
320	Gene expression profile in fibroblast growth factor 2-transformed endothelial cells. , 0, .		1
321	FGF/FGFR Axis-Blockade Leads to Anti-Tumor Activity in Waldenstrom's Macroglobulinemia By Silencing MYD88. Blood, 2020, 136, 43-44.	1.4	1
322	Liver DNA Damage by Chemical Carcinogens: Role of Thyroid Hormones. , 1988, , 129-135.		1
323	The Interaction of Basic Fibroblast Growth Factor (bFGF) With Heparan Sulfate Proteoglycans. , 1996, , 171-187.		1
324	β-Galactosylceramidase in cancer: more than a psychosine scavenger. Oncoscience, 2022, 9, 11-12.	2.2	1

#	Article	IF	CITATIONS
325	Liver genotoxic activity of an epoxide derivative of the hepatocarcinogenic β-blocker DL-ZAMI 1305. Cancer Letters, 1990, 55, 61-66.	7.2	0
326	MECHANISMS OF KAPOSIS-SARCOMA CELL SUPERNATANT-INDUCED VASCULAR CELL INVASION. International Journal of Oncology, 1995, 6, 539-46.	3.3	0
327	The italian 'Special Project on Angiogenesis'. Angiogenesis, 1997, 1, 20-21.	7.2	0
328	Comparative 3d-Morphometry of the Microvascular Unit In Tumors and Normal Tissues: Quantitative Studies on Corrosion Casts. Microscopy and Microanalysis, 1999, 5, 1198-1199.	0.4	0
329	Heparin Derivatives and Semisynthetic Biotechnological Heparins as Angiogenesis Inhibitors. Frontiers in Drug Design and Discovery, 2005, 2, 371-391.	0.3	0
330	The Zebrafish/Tumor Xenograft Angiogenesis Assay. , 2012, , 253-268.		0
331	FGF Ligand Traps for the Therapy of FGF-Dependent Tumors. , 2017, , 237-269.		0
332	Inactive VEGFR2(R1032Q) exerts proâ€oncogenic activity through heterodimerization with wildâ€ŧype receptor. FASEB Journal, 2021, 35, .	0.5	0
333	Interaction of Angiogenic Growth Factors with Endothelial Cell Heparan Sulfate Proteoglycans. , 2002, , 357-385.		0
334	New insights in the modulation of tumor angiogenesis. European Cytokine Network, 2009, 20, 157-157.	2.0	0
335	Is the Beta-Blocker DL-ZAMI 1305 a Tumor Promoter for Rat Liver?. , 1991, , 599-610.		0
336	Basic Fibroblast Growth Factor and Endothelial Cells: Receptor Interaction, Signal Transduction, Cellular Response-Dissociation of the Mitogenic Activity of bFGF from its Plasminogen Activator-Inducing Capacity. , 1992, , 79-89.		0
337	Human Basic Fibroblast Growth Factor: Structure-Function Relationship of an Angiogenic Molecule. , 1994, , 39-50.		0
338	Autocrine Role of Basic Fibroblast Growth Factor (bFGF) in Angiogenesis and Angioproliferative Diseases. , 1998, , 99-112.		0
339	Overcoming the Supportive Stroma-Induced Proliferation in Waldenstrom's Macroglobulinemia By Selective Inhibition of the FGF/FGF-Receptor Axis. Blood, 2019, 134, 1822-1822.	1.4	0
340	Quantification of Tumor Vasculature by Analysis of Amount and Spatial Dispersion of Caliber-Classified Vessels. Methods in Molecular Biology, 2021, 2206, 151-178.	0.9	0
341	Fibroblast Growth Factors. , 2021, , 1-11.		0
342	Fibroblast Growth Factors. , 2021, , 665-675.		0

#	Article	IF	CITATIONS
343	Cellular and molecular mechanisms of the human embryonic leads to fetal hemoglobin switch. Progress in Clinical and Biological Research, 1983, 134, 411-9.	0.2	0